Back To Search Instructions
Protocols
23 protocols meet the specified criteria
Disease Site: Leukemia, other
Protocol No.TitleStatus
0500000226Arizona Lymphoid Tissue and Blood Repository (ALTBR)Open
0800001145AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research SpecimensOpen
1100000610A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications (10-CBA)Open
1501629128AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B Lymphoblastic Leukemia (B-ALL)Open
1512277664APEC14B1: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome StudyOpen
1604498313Preclinical Investigation of Novel Therapeutic Agents for Hematological Malignancies Open
1606616633Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155)Open
1609876907A Phase I/II Study of Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide and/or BendamustineOpen
1610905065A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell TransplantOpen
1612040295Improving Transitions of Care for HSCT Recipients After DischargeOpen
1701114637Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease RegistryOpen
1702222208A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination with Azacitidine in Subjects with Higher-Risk Myelodysplastic Syndromes After Hypomethylating Agent-FailureOpen
1703305188A Randomized Phase 2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)Open
1706564897An observational study of patients with Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia in the USOpen
1707630812Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving Cytoreductive TherapyOpen
1708704370GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft Versus-Host DiseaseOpen
1708725986A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH 3)Open
1709807187A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid LeukemiaOpen
1709857266A retrospective review of prevention of fungal infections using fluconazole as prophylaxis in the adult and pediatric allogeneic stem cell transplant populationOpen
1711012625Safety and Efficacy of Filgrastim-sndz in Combination with Plerixafor followed by Post autologous stem cell infusion for Autologous peripheral blood stem cell transplantation Open
1711993805An Open-Label, Single Sequence, Crossover Drug-Drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in PatientsOpen
2002-0063Protocol for a Research Database For Hematopoieitc Stem Cell Transplantation and Marrow Toxic InjuriesOpen
27547A Phase 1/2 Study of INCB053914 in Subjects With Advanced MalignanciesNot Open